Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CATH phase 2 trial of REGN9933 and REGN7508 for prevention of PICC-associated venous thromboembolism
MOH_2024-07-15_013459Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in venous thromboembolism (VTE) comparing REGN9933 intravenous single dose, REGN7508 intravenous single dose and Matching placebo intravenous single dose (3 arms). Primary endpoint: Primary endpoint not reported. Planned start May 2024; status: not yet recruiting.
02
Drugs
amrecibartREGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2024-07-15_013459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-15_013459.